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S U M M A R Y
Objectives: To assess off-treatment virological relapse rates and to determine the role of hepatitis B
surface antigen (HBsAg) quantiﬁcation in predicting virological relapse after stopping entecavir (ETV)
treatment in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).
Methods: One hundred and twelve CHB patients for whom ETV was stopped in accordance with the
Asian Paciﬁc Association for the Study of the Liver guidelines stopping rules were enrolled. Patient HBsAg
and HBV DNA levels were monitored every 4–12 weeks during ETV treatment and after ETV cessation.
Post-treatment virological relapse was deﬁned as a serum HBV DNA level of >10 000 copies/ml after
stopping ETV treatment.
Results: The virological relapse rate at 52 weeks after stopping ETV was 48.2%. The post-treatment
virological relapse rate was signiﬁcantly higher in patients aged >50 years than in those aged <50 years
(p < 0.001), and the virological relapse rate was signiﬁcantly lower in patients with an HBsAg level <2.0
log10 IU /ml than in those with a level 2.0 log10 IU /ml at ETV cessation (p = 0.005). An HBsAg level of
2.5 log10 IU/ml at HBeAg seroconversion was the optimal cut-off value for predicting post-treatment
virological relapse (p < 0.001). In those aged <50 years and with HBsAg 2.5 log10 IU/ml at HBeAg
seroconversion, the relapse rate was only 5%. In patients with HBsAg 2.5 log10 IU/ml at HBeAg
seroconversion, 52.4% achieved HBsAg levels 2.0 log10 IU/ml at ETV cessation, while in those with
HBsAg >2.5 log10 IU/ml at HBeAg seroconversion, only 4.4% achieved this criterion.
Conclusions: HBsAg levels can help guide the timing of cessation of ETV treatment. HBsAg levels of
2.5 log10 IU/ml at HBeAg seroconversion may be a useful marker to predict virological relapse after the
cessation of ETV treatment in HBeAg-positive CHB patients.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic hepatitis B (CHB) is a major global health problem and a
leading cause of liver-related complications, including cirrhosis,
liver failure, hepatocellular carcinoma (HCC), and death. The goal
of nucleoside/nucleotide analog (NA) therapy for CHB is to
suppress the replication of hepatitis B virus (HBV) in a sustained
manner, and prevent disease progression to decompensated
cirrhosis and HCC.1–4 However, the durability of off-treatment
virological responses has not been fully estimated in patients in* Corresponding author. Tel.: +86-512-67780393; fax: +86-512-67780393.
E-mail address: ganjianhe@aliyun.com (J.-h. Gan).
http://dx.doi.org/10.1016/j.ijid.2015.10.019
1201-9712/ 2016 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).whom complete virological suppression is achieved with NA
therapy, and relapse rates after stopping NA treatment have not
been well established. According to the recommendations of the
Asian Paciﬁc Association for the Study of the Liver (APASL),4 NA
therapy should be stopped in hepatitis B e antigen (HBeAg)-
positive CHB patients after HBeAg seroconversion has persisted for
more than 12 months. However, some patients develop hepatitis
relapse after stopping NA therapy, even when the above
recommendation has been followed.5,6 Therefore, indexes to
monitor relapse rates after the cessation of NA treatment are
urgently required.
In large registration trials, entecavir (ETV) was found to be safe
and effective in NA-naı¨ve patients with CHB,7–9 and ETV is used
widely in the treatment of CHB patients in China. However,ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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positive patients, and if so, what the timing of cessation of ETV
treatment should be, remain controversial.
Quantitative hepatitis B surface antigen (HBsAg) tests can
indirectly reﬂect the HBV cccDNA level in liver tissue.10–13 Thus,
quantitative tests for serum HBsAg may predict virological relapse
after the cessation of lamivudine, adefovir, or telbivudine.14–19
However, reports on the dynamic quantitative monitoring of
serum HBsAg levels to predict virological relapse after the
cessation of ETV are scarce. The aim of the present study was to
analyze the correlation between dynamic serum HBsAg levels and
virological relapse in HBeAg-positive patients for whom ETV
treatment was stopped in accordance with the APASL guidelines.
This study explored the usefulness of HBsAg levels in predicting
virological relapse after ETV cessation.
2. Patients and methods
2.1. Patients
Between January 2009 and December 2011, a total of 136 NA-
naı¨ve, HBeAg-positive patients attended the Fifth People’s Hospital
of Wuxi, the First Afﬁliated Hospital of Soochow University, and
the Second Afﬁliated Hospital of Nanchang University. These
patients were selected for the present study if they fulﬁlled the
following criteria: (1) HBsAg positivity for more than 6 months,
alanine aminotransferase (ALT) level 2  the upper limit of
normal, and HBV DNA level 105 copies/ml before ETV treatment;
(2) history of ETV treatment for at least 2 years and cessation of
ETV treatment when HBeAg seroconversion was maintained for
>12 months.
Patients with any of the following were excluded: suspected or
imaging/biopsy-conﬁrmed liver cirrhosis before ETV treatment,
co-infection with hepatitis A, C, D, and/or E virus, alcoholic liver
disease, autoimmune diseases, cholestasis, malignant tumors,
severe heart diseases, diabetes, pregnancy, lactation, and history of
any NA treatment before ETV or an immune-regulating agent in the
past 6 months.
Virological response was deﬁned as HBV DNA being undetect-
able in serum samples tested using PCR assays (HBV DNA <100
copies/ml). HBeAg seroconversion was deﬁned as HBeAg disap-
pearance and HBeAg antibody appearance. Post-treatment viro-
logical relapse was deﬁned as a serum HBV DNA level of >10 000
copies/ml in two consecutive measurements made at least 1 month
apart after stopping ETV treatment. Written informed consent was
obtained from each subject before and after treatment. The Ethics
Committee of the Wuxi Fifth Afﬁliated Hospital of Jiangnan
University approved this study (WXFAH-No.1125).
2.2. Methods
Laboratory assessments were performed at baseline, every
4 weeks before HBeAg seroconversion and every 12 weeks after
HBeAg seroconversion during ETV treatment, and every 4–12 weeks
after the cessation of ETV treatment. The assessments included tests
for the biochemical indicators of liver function, serologic HBV
markers (including HBeAg and anti-HBe antibody), and serum HBV
DNA and HBsAg quantiﬁcation. HBV DNA and genotypes were tested
with a LightCycler Real-Time II PCR detection system (Roche,
Switzerland). The HBV DNA reagent kit was bought from Shanghai
Kehua Biotechnology Co. Ltd; this has a sensitivity of 100 copies/ml.
HBV genotypes were determined using a commercial real-time PCR
kit (Fosun Diagnostics, Shanghai, China). The kit detects HBV
genotype with a lower detection limit of 1000 copies/ml. HBV
markers were tested using a 1235 Time-Resolved Fluorescent
Immunity Analyzer (Perkin-Elmer Life Sciences Company, Finland),and measured with commercially available reagents (Kehua Biotech,
Shanghai, China) according to the manufacturer’s instructions. The
biochemical indicators of liver function were assessed using a
Hitachi 7600 fully automatic biochemical analyzer (Hitachi
High-tech Company, Japan). Quantitative tests for HBsAg were
performed using the i2000 Chemical Luminescent Immuno-
analyzer (Abbott, USA) and Abbott reagents, with a diagnostic
range from 0.05 IU/ml to 250 IU/ml. When the HBsAg level was >250
IU/ml, a special diluent was used to dilute the sample 100–1000
times, and precise quantitative tests were conducted.
2.3. Statistical analysis
Measurement data were expressed as the mean  standard
deviation. Differences in measurement data were examined using the
t-test and analysis of variance. Enumerative data were analyzed using
the Chi-square test or Fisher’s exact test. Univariate and multivariate
analyses were performed using Cox proportional hazards regression
models to identify factors associated with virological relapse.
Receiver operating characteristic (ROC) curve analysis was used to
deﬁne the best cut-off point of HBsAg level for predicting virological
relapse after ETV cessation. The statistical analysis was performed
using SPSS for Windows v. 16.0 software (SPSS Inc., Chicago, IL, USA).
A p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Baseline characteristics of relapsers and non-relapsers
A total of 136 CHB patients met the selection criteria. Twelve
patients with liver cirrhosis and 12 patients who were followed up
for less than 24 weeks were excluded. Thus, 112 CHB patients were
included in the present study. Of these, 74 were men and 38 were
women. The age range of the patients was 22–63 years (mean
40.1  11.2 years). The period of antiviral treatment for these
112 CHB patients was 26–40 months (mean 30.7  3.5 months).
The observation period after ETV cessation was 52 weeks. The mean
age of the relapsers was 46.1  9.8 years and of non-relapsers was
34.6  9.6 years; the difference in age was statistically signiﬁcant
(p < 0.001). The patients were divided into four subgroups based on
their age at ETV commencement: group A, <30 years (n = 32); group
B, 30–39 years (n = 30); group C, 40–49 years (n = 24); group D, 50
years (n = 36). The respective cumulative rates of post-treatment
virological relapse in groups A, B, C, and D were 25.0%, 36.7%, 54.2%,
and 84.6%, respectively, at 52 weeks. The virological relapse rate was
signiﬁcantly higher in group D than in groups A, B, and C (all
p < 0.001). No signiﬁcant difference in virological relapse was noted
among groups A, B, and C (p = 0.082) (Figure 1).
The baseline HBV DNA levels at ETV commencement in
relapsers was 6.8  1.0 log10 copies/ml and in non-relapsers was
6.3  0.8 log10 copies/ml; the difference in HBV DNA levels was
statistically signiﬁcant (p = 0.015) (Figure 2).
The virological relapse rates at 12 weeks, 13–24 weeks, 25–36
weeks, and 37–52 weeks were 7.1% (8/112), 24.1% (27/112), 11.7%
(13/112), and 5.4% (6/112), respectively. The virological relapse
rate at 52 weeks was 48.2% (54/112; Figure 1), and one patient
became HBsAg loss during follow-up for 52 weeks. The baseline
characteristics of the relapsers and non-relapsers are shown in
Table 1.
3.2. Correlation between baseline HBsAg level at ETV commencement
and HBV relapse after stopping ETV treatment
The baseline HBsAg levels at the commencement of ETV
treatment did not differ signiﬁcantly between the relapsers and
non-relapsers (p = 0.361; Table 1). In patients with a baseline
Figure 1. Virological relapse rate up to week 52.
Figure 2. HBV DNA levels during ETV treatment and after ETV cessation (ETV,
entecavir).
Figure 3. HBsAg levels at different time-points during ETV treatment (HBsAg,
hepatitis B surface antigen; ETV, entecavir).
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ml at ETV commencement, the HBV relapse rate at 52 weeks after
stopping the ETV treatment was 15.8% (3/19). In contrast, in those
with baseline HBsAg >3.0 log10 IU/ml and/or HBV DNA >6.0 log10
copies/ml, the virological relapse rate was 54.8% (51/93). The
difference was statistically signiﬁcant (p = 0.002).
3.3. Correlation between HBsAg levels at 12 weeks of ETV treatment
and HBV relapse after ETV discontinuation
The HBsAg levels at 12 weeks of ETV treatment did not
signiﬁcantly differ between the relapsers and non-relapsers
(p = 0.252; Figure 3). However, in patients in whom the HBsAg
level had declined by 1.0 log10 IU/ml at 12 weeks of treatment,
the virological relapse rate was 7.7% (1/13), whereas this rate was
53.5% (53/99) in those whose HBsAg level at 12 weeks had declined
by <1.0 log10 IU/ml. The difference in relapse rates was statistically
signiﬁcant (p = 0.002).
3.4. Correlation between HBsAg level at HBeAg seroconversion and
HBV relapse after ETV cessation
The HBsAg level at the time of HBeAg seroconversion in
virological relapsers was 3.75  0.57 log10 IU/ml and in non-
relapsers was 3.12  0.72 log10 IU/ml (p < 0.001). A ROC curve of
the HBsAg levels in the 112 patients at the time of HBeAg
seroconversion was plotted. The area under the ROC curve was
0.751 (95% conﬁdence interval (CI) 0.660–0.842, p < 0.001; Figure 4).
The optimal cut-off value of HBsAg level at HBeAg seroconversion
was 2.72 log10 IU/ml. An HBsAg level of 2.5 log10 IU/ml was used as a
marker for predicting virological relapse. In patients with HBsAg
levels 2.5 and >2.5 log10 IU/ml at the time of at HBeAgTable 1
Comparison of baseline characteristics between relapsers and non-relapsers
Variables Total
(n = 112
Age, years, mean (SD) 40.1  1
Sex, male/female, n 74/38 
ALT at ETV commencement, IU/l, mean (SD) 195.6  
Total bilirubin, mg/dl, mean (SD) 2.2  0.5
HBV DNA at ETV commencement (log10 copies/ml), mean (SD) 6.5  1.0
HBV genotype, B/C, n 66/46 
Baseline HBsAg at ETV commencement (log IU/ml), mean (SD) 3.8  0.7
Time of virological response, weeks, mean (SD) 20.6  9
Course of treatment, months, mean (SD) 30.7  3
SD, standard deviation; ALT, alanine aminotransferase; ETV, entecavir; HBV, hepatitis Bseroconversion, the virological relapse rates were 9.5% (2/21) and
57.1% (52/91), respectively (Chi-square = 15.496, p < 0.001).
Because age and HBsAg level at HBeAg seroconversion were
independent predictors of virological relapse, the patients were
divided into three subgroups based on their age (<50 and 50
years) and HBsAg level at HBeAg seroconversion (2.5 log10 IU/ml
and >2.5 log10 IU/ml) as follows: group E with age <50 years and
HBsAg level 2.5 log10 IU/ml, group F with age <50 years and
HBsAg level >2.5 log10 IU/ml, and group G with age 50 years
and regardless of their HBsAg level; the virological relapse rates in
groups E, F, and G were 6.7% (1/15), 43.7% (31/71), and 84.6%
(22/26), respectively. The virological relapse rate was signiﬁcantly
higher in group G than in groups E and F (all p < 0.001) and higher
in group F than in group E (p = 0.007).)
Relapsers
(n = 54)
Non-relapsers
(n = 58)
p-Value
1.2 46.1  9.8 34.6  9.6 <0.001
39/15 35/23 0.232
90.1 179.9  87.6 211.2  100.6 0.075
 2.3  0.3 2.1  0.4 0.761
 6.8  1.1 6.3  0.7 0.015
29/25 37/21 0.338
 3.9  0.7 3.7  0.6 0.361
.4 22.4  10.0 19.0  8.5 0.06
.5 30.2  3.8 31.2  3.1 0.112
 virus; HBsAg, hepatitis B surface antigen.
Figure 4. Area under the receiver operating characteristic curve of HBsAg at different time-points (HBsAg, hepatitis B surface antigen; ETV, entecavir).
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relapse after ETV cessation
The HBsAg levels at ETV cessation differed signiﬁcantly
between the relapsers and non-relapsers (3.58  0.54 log10 IU/ml
vs. 2.99  0.64 log10 IU/ml, t =  2.866, p = 0.005; Figure 5). The area
under the ROC curve of the HBsAg levels at ETV cessation in the
112 patients was 0.671 (95% CI 0.572–0.770, p = 0.002; Figure 4) and
could be used to predict virological relapse. The optimal cut-off value
of HBsAg level at ETV cessation to predict virological relapse was
2.24 log10 IU/ml. In patients whose HBsAg levels at ETV cessation
were 2.0 log10 and >2.0 log10 IU/ml, the virological relapse rates
were 13.3% (2/15) and 53.6% (52/97), respectively (p = 0.005). In
patients whose HBsAg was 2.5 log10 IU/ml at HBeAg seroconversion,
52.4% achieved HBsAg levels 2.0 log10 IU/ml at ETV cessation, while
in patients whose HBsAg was >2.5 log10 IU/ml at HBeAg seroconver-
sion, only 4.4% achieved this criterion.
3.6. Correlation between HBsAg level at 12 weeks after ETV cessation
and HBV relapse after ETV cessation
The virological relapse rate at 52 weeks after the cessation of
ETV treatment was 81.3% (26/32) in patients whose HBsAg levels
increased by 1.0 log10 IU/ml at 12 weeks after ETV cessation. The
relapse rate was 48.7% (19/39) in patients whose HBsAg levelsTable 2
Factors predictive of post-treatment HBV relapse for 112 patients
Factors Univariate analysis 
HR 95% CI 
Age 1.054 1.031–1.077 
Sex 0.738 0.407–1.339 
ALT at ETV commencement 0.997 0.994–1.001 
HBV DNA at ETV commencement 1.291 1.010–1.649 
HBV genotype 1.442 0.844–2.464 
Virological response time 1.024 0.997–1.052 
HBsAg at ETV commencement 1.103 0.733–1.661 
HBsAg level at HBeAg seroconversion 2.743 1.784–4.219 
HBsAg level at ETV cessation 2.356 1.494–3.716 
HBV, hepatitis B virus; HR, hazard ratio; CI, conﬁdence interval; ALT, alanine aminotra
antigen.increased by <1.0 log10 IU/ml at 12 weeks after ETV cessation. The
relapse rate was 22.0% (9/41) in patients whose HBsAg levels did
not increase or decreased at 12 weeks after the cessation of ETV
treatment. There was a signiﬁcant difference among these three
groups (p < 0.001).
3.7. Multivariate Cox model analysis
A univariate analysis of age, sex, genotypes, baseline ALT,
baseline HBV DNA, baseline HBsAg level at ETV commencement,
virological response time (weeks), HBsAg level at HBeAg serocon-
version, and HBsAg level at ETV cessation was ﬁrst conducted. The
factors that showed statistically signiﬁcant results were then
selected for multivariate Cox model analysis, namely age, baseline
HBV DNA, HBsAg level at HBeAg seroconversion, and HBsAg level
at ETV cessation. Factors that signiﬁcantly affected virological
relapse rates after ETV cessation were age (p = 0.001), HBsAg level
at HBeAg seroconversion (p = 0.002), and HBsAg level at ETV
cessation (p = 0.037), in that order (Table 2).
4. Discussion
Previous studies in European and American subjects have
indicated that the maintenance rate of virological response after
the cessation of NA therapy reaches 80–90%; however, this rate inMultivariate analysis
p-Value HR 95% CI p-Value
<0.001 1.040 1.016–1.065 0.001
0.318
0.128
0.042 1.164 0.919–1.475 0.208
0.180
0.079
0.638
<0.001 2.162 1.338–3.493 0.002
<0.001 1.679 1.032–2.733 0.037
nsferase; ETV, entecavir; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e
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virological relapse rate in HBeAg-positive patients treated with
ETV and clevudine,22 and Ridruejo et al. reported a 26% virological
relapse rate in HBeAg-positive patients at a median of 48 weeks
after the discontinuation of ETV treatment.23 This study also
showed a similar high virological relapse rate (48.2%) in HBeAg-
positive patients at 52 weeks after ETV cessation. Most of the
patients relapsed at 12–36 week after ETV cessation; the
virological relapse rate in patients whose HBsAg level had
increased 1.0 log10 IU/ml at 12 weeks after ETV cessation was
much higher (81.3%) than that of patients whose HBsAg level
increased slowly or remained decreased. Therefore, it is necessary
to monitor HBV DNA levels and HBsAg levels closely after ETV
cessation to predict and detect virological relapse in a timely
manner (Figure 5).
Recent studies have found that quantitative tests for serum
HBsAg levels and HBV DNA and dynamic monitoring of these levels
can predict the effects of antiviral treatment with peginterferon
alfa-2a and the relapse of hepatitis after medication cessation.24,25
Chen et al. reported that a higher baseline HBsAg level at ETV
commencement was an independent predictor of clinical relapse
and that the baseline HBV DNA level was not associated with
clinical relapse in HBeAg-positive CHB patients.26 Seto et al.
reported that baseline and subsequent serial HBsAg levels had no
association with virological relapse in HBeAg-negative CHB
patients. The authors explained this as the decoupling of serum
HBsAg and HBV DNA production in HBeAg-negative disease.27 In
the HBeAg-positive CHB patients in the present study, it was also
found that the baseline HBsAg level at ETV commencement was
not an independent predictor of virological relapse. Baseline HBV
DNA levels at ETV commencement were signiﬁcantly higher in
relapsers than in non-relapsers, but multivariate Cox model
analysis showed baseline HBV DNA not to be an independent risk
factor; the reason for this is the large overlap in HBV DNA levels in
relapsers and non-relapsers. However, the present data show that
patients who had low baseline HBsAg levels 3.0 log10 IU/ml and
baseline HBV DNA levels 6.0 log10 copies/ml at ETV commence-
ment had low relapse rates after ETV cessation (15.8%, 3/19). This
may be useful for physician reference.
Chan et al. reported that the reduction in HBsAg levels from
baseline to the end of treatment could predict post-lamivudine
virological relapse rates.28 Wursthorn et al. reported that a rapid
decrease in HBsAg level after oral telbivudine treatment for
24 weeks could achieve a high rate of HBeAg seroconversion and
that long-term treatment could eliminate HBsAg, which could beFigure 5. HBsAg levels at different time-points after ETV cessation (HBsAg, hepatitis
B surface antigen; ETV, entecavir).used to predict the relapse of hepatitis after drug cessation.29 Data
from the present study also show that a rapid decrease in HBsAg
(HBsAg level decrease 1.0 log10 IU/ml) after 12 weeks of
ETV treatment could result in a low virological relapse rate (7.7%,
1/13).
In this study, it was found that age and HBsAg level at HBeAg
seroconversion were independent predictors of virological relapse.
Based on subgroup data combining age and HBsAg level at HBeAg
seroconversion, it is recommended that patients aged 50 years
should not stop therapy regardless of their HBsAg level because
their relapse rate was 84.6% (22/26). Patients aged <50 years and
with an HBsAg level 2.5 log10 IU/ml at HBeAg seroconversion may
stop ETV therapy based on the APASL recommended stopping
rules, because their relapse rate was only 6.7% (1/15). Patients aged
<50 years and with an HBsAg level >2.5 log10 IU/ml at HBeAg
seroconversion still showed a high relapse rate (43.7%, 31/71).
Furthermore, it was found that only a few patients (4.4%, 4/91)
could achieve HBsAg levels <2.0 log10 IU/ml under the current
APASL recommended consolidation time. Thus it is recommended
that these patients should undergo regular monitoring of their
HBsAg levels and should stop ETV therapy only when their HBsAg
level is <2.0 log10 IU/ml.
Liang et al. reported that the HBsAg level at the end of
treatment was related to a low relapse rate; only 9% of patients
with HBsAg levels 2.0 log10 IU/ml had a virological relapse.30
The present study showed the relapse rate to be 13.3% (2/15)
when the HBsAg levels were <2.0 log10 IU/ml at ETV cessation,
which is consistent with the previous study. This phenomenon
should be investigated further because it might be that an HBsAg
level <2.5 log10 IU/ml at HBeAg seroconversion will be a more
useful marker and earlier index than an HBsAg level <2.0 log10 IU/
ml at ETV cessation to guide and predict the timing of stopping
ETV therapy.
This study has a few limitations. First, this was a retrospective
study and therefore a selection bias is possible. Second, the HBsAg
level at HBeAg seroconversion was difﬁcult to determine precisely
in terms of the exact time of HBeAg seroconversion, because these
seromarkers were monitored at regular intervals of 4 weeks or
even longer. Third, this study did not determine whether a
different duration of prolonged consolidation therapy would
inﬂuence the relapse rate, and the follow-up period after ETV
cessation was only 52 weeks; this is too short to observe the long-
term relapse rate. Finally, HBeAg seroconverters under ETV
therapy are only a minority, and cessation of therapy is not a
useful option for the majority of patients.
In conclusion, the virological relapse rate at 52 weeks after
stopping ETV was 48.2%. The variation in HBsAg levels during ETV
treatment and after ETV cessation could help guide the timing of
cessation of ETV treatment. A serum HBsAg level 2.5 log10 IU/ml
at the time of HBeAg seroconversion may be a useful marker to
predict virological relapse after the cessation of ETV treatment in
HBeAg-positive CHB patients.
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